who manufactures glp 1 drugs 2025’s Breakthrough GLP-1 Obesity Treatments: Top Companies & Innovations GLP-1 Agonists Market Report 2025-2033,

32(suppl_2)

Steady dose escalation to higher doses than for glycaemic control are indicated if: BMI is 30 kg/m 2 , or BMI 27 to 30 kg/m 2 , and for the range 2730 kg/m 2 if there is one weight-related comorbidity (hypertension, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea, prediabetes or T2D

These were originally investigated for diabetes, on the theory that GLP-1 increases insulin and thus decreases blood sugar

Some insurance companies list GLP-1 medications used for weight loss as a coverage exclusion, which means that even if a patient meets FDA-approved criteria and would benefit from using the medication, the plan will not pay for the medication, she says